High dose ifosfamide and adriamycin in the treatment of soft tissue sarcomas

Background. To evaluate the efficacy and toxicity of dose-dense high dose ifosfamide and adriamycin in the treatment of locally advanced and metastatic soft tissue sarcomas. Materials and methods. 26 patients where included in the interim analysis by the end of 2009. Dose dense high dose (DDHD) AI ifosfamide 2000 mg/m² IV 1-5 days with adriamycin 60 mg/m² IV day 1 with GM-CSF support 6-14 once in 2 weeks was used in 23 STS patients. Male 60%, female 40% with the median age of 42 years old (22-63 years old). From 26 patients at the beginning of DDHD AI chemotherapy 10 patients were locally advanced, and 16 - with distant metastases. Tumor assessment was made according to RECIST criteria after every 2 cycles. Histology - synovial 11 pts, MFH - 3 pts, lipo - 6 pts, leiomyo - 1 and 2 NOS sarcomas. Results. Objective response has achieved in 43,5% (CR - 13,1%, PR - 30,4%), stable disease - 39,1%, disease progression in 17,4%. Toxicity profile was manageable and mild: leucopenia 56% with Gr 3-4 23%, neutropenia - 47% (Gr 3-4 - 9%), anemia - 52% with no Gr 3-4, thrombocytopenia 17% (Gr 3-4 - 9%). Conclusion. This chemotherapy regimen seems to be very active in the treatment of STS patients with mild and manageable toxicity profile and needs further evaluation of the impact on overall survival and time to progression. This trial is still ongoing.

soft tissue sarcoma, chemotherapy, dose-dense ifosfamide, doxorubicin

1. Jemal A., Siegel R., Ward E. et al. Cancer statistics. J. Clin. 2009, v. 59, p. 225.

2. Fletcher C.D.M., Unni K.K., Mertens F. Eds. Pathology and Genetics of tumors of soft tissue and bone. Lyon, France. IARC. 2002.

3. Алиев М.Д. Введение в онкоортопедию. Саркомы костей, мягких тканей и опухоли кожи. 2009, v. 1, p. 14-17.

4. Lawrence W.Jr., Donegan W.L., Natarajan N. et al. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann. Surg. 1987, v. 205, p. 349.

5. Goldberg Brynn R. et al. Soft Tissue Sarcoma: An Overview. Orthop Nurs. 2007 Jan-Feb, v. 26 (1), p. 4-11, quiz 12-3.

6. Verma S., Younus J., Stys-Norman D. et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer. Treat. Rev. 2008, v. 34, p. 339.

7. Comandone A., Bretti S., Bertetto O., Oliva C., Bergnolo P., Bumma C. Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas. Anticancer. Res. 2000, v. 20, p. 2077-2080.

8. Schutte J., Mouridsen H., Steward W. et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer. Chemother. Pharmacl. 1993, v. 31, p. 204-209.

9. Loehrer P.J., Sledge G.W., Nicaise C. et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J. Clin. Oncol. 1989, v. 7, p. 1655-1659.

10. Shailendra Verma, Jawaid Younus, Denise Stys-Norman et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer. Treatment. Reviews. 2008, v. 34, p. 339-347.

11. Fausto Badellino, Salvatore Toma. Treatment of Soft Tissue Sarcoma: A European Approach. Surg. Oncol. Clin. N Am. 2008, v. 17, p. 649-672.

12. Schutte J., Mouridsen H.T, Steward W et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer. Chemother. Pharmacol. 1993, v. 31, Suppl 2, р. 204-209.

13. Keohan M.L., Taub R.N. Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin. Oncol. 1997, v. 24, p. 572.

14. Bay J.O., Ray-Coquard I., Fayette J. et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int. J. Cancer. 2006, v. 119, p. 706.

15. Hensley M.L., Maki R., Venkatraman E. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 2002, v. 20, p. 2824.

16. Leu K.M., Ostruzka L.J., Shewach D. et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 2004, v. 22, p. 1706.

17. Garcia-Carbonero R., Supko J.G., Manola J. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft-tissues refractory to chemotherapy. J. Clin. Oncol. 2004, v. 22, p. 1480-1490.

18. Le Cesne A., Blay J.Y, Judson I. et al. Phase II study of ET- 743 in advanced soft-tissues sarcomas: a European Organization for the Research and Treatment of Cancer (EORTC) soft-tissue and bone sarcoma group trial. Clin. Oncol. 2005, v. 23, p. 576-584.

19. Yovine A., Riofrio M., Blay J.Y. et al. Phase II study of acte- nascidin-743 in advanced pretreated soft-tissue sarcoma patients. J. Clin. Oncol. 2004, v. 22, p. 890-899.

20. Maki R.G., D’Adamo D.R., Keohan M.L. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 2009, v. 27, p. 3133.

21. Hartmann J.T., Mayer F., Shleicher J. et al. Bendamustine hydrochloride in patients with refractory soft-tissue sarcoma: a noncomparative multicenter phase II study of the German sarcoma group (AIO-001). Cancer. 2007, v. 110, p. 861.

22. Le Cesne A., Judson I., Crowther D. et al. Randomized phase III study comparing conventional-dose doxorubicin plus if- osfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-marophage colony-stimulating factor in advanced soft-tissue sarcomas: a trial of the European organization for research and treatment of can- cer/soft tissue and bone sarcoma group. J. Clin. Oncol. 2000, v. 18, p. 2676.

23. Maurel J., Lopez-Pousa A., de Las, Penas R. et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J. Clin. Oncol. 2009, v. 27, p. 1893.

24. Patel S.R., Vadhan-Raj S., Burgess M.A. et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am. J. Clin. Oncol. 1998, v. 21(3), p. 317-21.

25. Patel S.R., Vadhan-Raj S., Papadopolous N. et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J. Clin. Oncol. 1997, v. 15 (6), p. 2378-2384.